MedTrace Logo

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

NCT01259089 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-09-11

Study results available
· View outcomes & findings →

Summary

Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.

Conditions

Interventions

DRUG

erlotinib hydrochloride

Given orally

DRUG

Hsp90 inhibitor AUY922

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

needle biopsy

Undergo image-guided needle biopsy (correlative studies)

GENETIC

mutation analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Melissa Johnson · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-27
Primary Completion
2013-06-04
Completion
2014-09-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01259089 on ClinicalTrials.gov